The summaries are free for public
use. The Chronic Liver Disease
Foundation will continue to add and
archive summaries of articles deemed
relevant to CLDF by the Board of
Trustees and its Advisors.
Abstract Details
Diabetes Medications and Risk of Hepatocellular Carcinoma
Hepatology. 2022 Mar 3. doi: 10.1002/hep.32439. Online ahead of print.
Maria Corina Plaz Torres1, Ariel Jaffe2, Rachel Perry234, Elisa Marabotto1, Mario Strazzabosco2, Edoardo G Giannini1
Author information
Gastroenterology Unit, Department of Internal Medicine, IRCCS-Ospedale Policlinico San Martino, University of Genoa, Genoa, Italy.
Liver Center, Department of Internal Medicine, Yale University School of Medicine, New Haven, Connecticut, USA.
Section of Endocrinology, Department of Internal Medicine, Yale University School of Medicine, New Haven, Connecticut, USA.
Department of Cellular and Molecular Physiology, Yale University School of Medicine, New Haven, Connecticut, USA.
Abstract
Type 2 diabetes mellitus is a recognized risk factor for hepatocellular carcinoma in patients with liver disease, independent from the aetiology of their liver disease. Hence, prevention and treatment of type 2 diabetes mellitus and its underlying cause, insulin resistance, should be considered a treatment-target for patients with liver disease. The drug armamentarium for diabetes is wide and is comprised of agents with insulin sensitizing activity, agents which stimulate insulin secretion, insulin itself, and agents that reduce gastrointestinal and urinary glucose absorption. From an endocrinology perspective, the main goal of treatment is the achievement of euglycemia; however, in patients at risk of, or with known underlying liver disease, the choice of diabetic medication as it relates to potential hepatic carcinogenesis remains complex and should be carefully considered. In the last decade, increasing evidence has suggested that metformin may reduce the risk of hepatocellular carcinoma, whereas evidence for other classes of diabetic medications, particularly some of the newer agents including the sodium glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists is fewer and often inconsistent. In this review, we aim to summarize the current evidence on the potential effects of the most widely used diabetic agents on liver cancer tumorigenesis.